3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
1
Status
Unknown
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
7
Ovarian Neoplasms
4
Stomach Neoplasms
3
Neoplasm Metastasis
3
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Multiple Myeloma
2
Lymphoma
2
Endometrial Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Recurrence
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms, Unknown Primary
1
Mouth Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Laryngeal Neoplasms
1
Hypopharyngeal Neoplasms
1
Hematologic Neoplasms
1
Glioma
1
Gastrointestinal Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Interventions
Carboplatin
361
Pemetrexed
276
Cisplatin
230
Paclitaxel
213
Docetaxel
205
Gemcitabine
160
Erlotinib Hydrochloride
150
Bevacizumab
132
pembrolizumab
129
Radiotherapy
114
Nivolumab
88
durvalumab
84
Drug Therapy
84
osimertinib
82
atezolizumab
58
Vinorelbine
53
Gefitinib
53
Radiosurgery
50
Cetuximab
39
Taxes
37
130-nm albumin-bound paclitaxel
36
Ipilimumab
34
anlotinib
33
Surgical Procedures, Operative
33
Magnetic Resonance Spectroscopy
33
Etoposide
30
Albumin-Bound Paclitaxel
29
tislelizumab
27
icotinib
27
aflutinib
26
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Carcinoma, Non-Small-Cell Lung
×
ipatasertib
×
Clear all
NCT04467801
2023-11-07
Ipat-Lung
University of Kansas Medical Center
Phase 2
Unknown
60 enrolled
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled